Last reviewed · How we verify
NCT03853681: VACTEVIH
Study on the Response to Tetanus Vaccination of People Living With HIV
NA trial testing additional blood sampling in HIV Infections in 210 participants. Completed in 24 February 2020.
11 September 2019
Quick facts
| Lead sponsor | Centre Hospitalier de Niort |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 210 |
| Start date | 11 March 2019 |
| Primary completion | 11 September 2019 |
| Estimated completion | 24 February 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- additional blood sampling — full drug profile →
Conditions studied
- HIV Infections — all drugs for HIV Infections →
Sponsor
Centre Hospitalier de Niort
Who can join
Adults 18 to 65, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The response to primary tetanus immunization of HIV-infected children is lower than that of uninfected children. Response to tetanus toxoid (TT) booster doses in adults living with HIV who have received primary vaccination prior to infection is not known. Currently, it is recommended to have a TT booster for people living with HIV (PLHIV) every 10 years. In general population, this recall is made only at 25, 45 and 65 years, then every 10 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03853681
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of additional blood sampling
Trials testing the same drug.
- NCT04231500 — The Skin Microbiome in Graft Versus Host Disease · active not recruiting
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
- NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting
Other Centre Hospitalier de Niort trials
Trials by the same sponsor.
- NCT06346119 — Evaluation of the Impact of Touch Relaxation in Sedated Intubated Patients Hospitalized in Intensive Care at Niort Hospi · NA · recruiting
- NCT05624437 — BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus · completed
- NCT03897855 — Memory Inhibition and Delayed Onset Post-traumatic Stress Disorder in Older Subjects · NA · completed
- NCT03801551 — Validation of a Tool for the Dimensional Assessment of Apathy in a Population Suffering From Schizophrenia. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03853681 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Niort
- Last refreshed: 5 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03853681.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing